Home » Books » Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary

Download Implementing a National Cancer Clinical Trials System for the 21st Century
Second Workshop Summary (Epub & Pdf)

Overview :

Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary by An American Society of Clinical Oncology and Institute of Medicine Workshop Details

The National Clinical Trials Network (NCTN), supported by the National Cancer Institute (NCI), played a key role in cancer research and in determining the level of care for cancer patients…

Implementing a National Cancer Clinical Trials System for the 21st Century synopsis

The National Clinical Trials Network (NCTN), supported by the National Cancer Institute (NCI), played a key role in cancer research and in determining the level of care for cancer patients for more than 50 years. NCTN, formerly known as the NCI clinical trial group, is known by more than 2,100 institutions and 14,000 investigators, who enroll more than 20,000 cancer patients in clinical trials each year across the United States and internationally.

Recognizing the recent transformational developments in cancer research that require updating in how cancer clinical trials are conducted, as well as other inefficiencies and challenges hampering the National Cancer Clinical Trials program, the National Institute of Inheritance asked the IOM to prepare a set of recommendations to improve federal funding for the clinical cancer trial system . These recommendations were published in the 2010 report, the National Clinical Cancer Experiment System for the 21st Century: Reactivation of the NCI Cooperative Program.

In early 2011, the NCPF and the American Society of Clinical Oncology (ASCO) held a workshop in which stakeholders discussed the changes they planned to implement in response to IOM's goals and recommendations. Two years later, from 11 to 12 February 2013, in Washington, DC, NCPF and ASCO appealed to stakeholders to report on the changes they have made so far to address IOM recommendations.

In this workshop, representatives of NCI, NCTN, Comprehensive Cancer Centers, Patient Protection Groups, the Food and Drug Administration (FDA), industry, and other stakeholders highlighted the progress that has been made in achieving the goals of a renewed national cancer clinical trial system. The implementation of the National Clinical Trials System for Cancer 21 is a summary of this workshop.



Please don't review this Book if you received a freebie for writing this review, or if you're connected in any way to the owner.